Pricing Log in Create free account
Friday 6 November 2026 Export IRMD’s income statement to Excel — free account

iRadimed Corporation

IRMD Healthcare Medical Devices

iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024.

Revenue
+14.2%
EPS
+15.9%
Free cash flow
+18.6%

Quarter to September 2026, against a year earlier

84.20 1.34 −1.57%
Market cap
$1.1B
P/E
44.9×
Fwd P/E
39.6×
Dividend yield
0.91%
F-score
6/9
Altman Z
55.62
Beneish M
−2.55
Dividend safety
40/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 15.51
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 6 4 1 5 4 4 2 — — 1 — —
Insider Ownership 34.86%

Capital & Financial Ratios $m

Size
Market Cap 1,090.00
Revenue ttm 89.34
Net income ttm 23.98
Free cash flow ttm 25.61
Net debt Q (63.29)
Valuation
P/E 44.90 (above 35: high)
Forward P/E 39.60 (above 35: high)
Price / sales 12.15 (above 10: high)
Forward P/S Powerpack
Price / FCF 44.05
Price / book 10.19 (above 6: high)
Financial health
Current ratio Q 8.99 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +14.15% (above 0%: growing)
Operating income growth Q +19.11% (above 0%: growing)
EPS, this year +8.64%
EPS, next year A +16.22% (at or above 15%: strong)
Revenue, next year A +9.85%
EPS, past 5 yrs +73.91% (at or above 15%: strong)
EPS, next 5 yrs A +11.50%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 11.4×, against a ten-year median of 7.7×; over the ten years it ranged from 2.0× in 2017 to 15.1× in 2026.
P/E against its own 10 years 61.46%
10-year low 10-year high
P/S against its own 10 years 85.96%
10-year low 10-year high
P/B against its own 10 years 90.83%
10-year low 10-year high
EV/Sales against its own 10 years 87.61%
10-year low 10-year high
EV/FCF against its own 10 years 48.22%
10-year low 10-year high

Dividends

Yield
0.91%
Annual rate
0.77
Payout ratio
41.2%
Growth, 2023–26
+58.7%/yr
  1. 0.15 ’23
  2. 0.45 ’24 +200
  3. 0.68 ’25 +51
  4. 0.60 ’26 −12
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 50 52 51 63
Receivables 12 11 14 14
Inventory 13 10 12 13
Other — — — —
76 75 81 93
2023 2024 2025 Q'26
Payables 2 2 2 2
ST’ Debt — — — —
Other 0 1 0 0
16 9 10 10

Compound Annual Growth %

10y 5y 3y
Sales 10.25% 21.45% 16.28%
Cash Flow 12.55% 33.80% 35.43%
Earnings 11.56% 75.02% 20.56%
Book Value 11.47% 9.04% 8.70%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate 0.45 Actual 0.49

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY25 0.43 0.42 Miss by 0.01
Q2 FY25 0.45 0.49 Beat by 0.04
Q4 FY25 0.49 0.54 Beat by 0.05
Q1 FY26 0.45 0.49 Beat by 0.04

EPS $

Mar Jun Sep Dec Year
’26 0.45 0.41 0.51 — —
’25 0.37 0.45 0.43 0.50 1.75
’24 0.32 0.38 0.40 0.40 1.50
’23 0.27 0.33 0.40 0.36 1.35
’22 0.20 0.26 0.27 0.29 1.02
’21 0.11 0.12 0.20 0.31 0.74
’20 0.14 (0.17) 0.09 0.05 0.11
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 22 20 24 — —
’25 20 20 21 23 84
’24 18 18 18 19 73
’23 15 16 17 17 66
’22 12 13 13 15 53
’21 9 10 11 12 42
’20 9 7 8 9 32
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 8 6 7 — —
’25 4 8 7 6 25
’24 4 7 9 6 26
’23 5 4 1 4 13
’22 1 2 4 3 10
’21 1 4 3 3 11
’20 1 1 1 2 6
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 8 5 7 — —
’25 0 5 6 6 17
’24 3 5 5 3 17
’23 (2) 3 1 3 5
’22 1 1 3 3 8
’21 1 3 3 3 11
’20 1 1 1 2 5
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 32 23 30 39 32 42 53 66 73 84 89 +11.1% 92 104 115 +11.1%
Gross margin, % 81.06 75.87 76.31 77.11 74.33 76.65 77.45 76.50 76.94 76.75 75.51 (4.3) pt
EBT 11 1 6 9 (1) 10 16 22 24 28 31 +11.2%
EBT margin, % 33.70 6.05 20.36 23.48 (1.94) 23.52 30.36 33.16 33.14 33.84 34.83 +0.1 pt
Net income 7 0 6 10 1 9 13 17 19 22 24 +13.5%
Per share, $
Per share, $ Revenue 3.00 2.17 2.83 3.41 2.62 3.39 4.24 5.20 5.78 6.59 6.99 +9.1%
Earnings 0.67 0.05 0.59 0.85 0.11 0.76 1.02 1.36 1.52 1.77 1.89 +11.4%
Cash flow 0.87 0.32 0.69 0.91 0.48 0.91 0.80 1.07 2.02 1.96 2.12 +9.5%
Capex (0.14) (0.08) (0.02) (0.04) (0.05) (0.06) (0.15) (0.64) (0.70) (0.66) (0.12) +18.8%
Free cash flow 0.73 0.24 0.66 0.86 0.43 0.85 0.65 0.43 1.33 1.30 2.00 +6.6%
Book value 2.95 3.10 3.90 4.92 5.06 5.85 5.86 5.67 6.85 7.44 8.33 +10.8%
Shares, m 11 11 11 11 12 12 13 13 13 13 13 +1.8%
Valuation, ×
Valuation, × P/E 16.47 306.00 41.46 27.19 190.00 61.61 27.92 34.77 35.95 54.96 44.90 79.6
P/S 3.73 7.05 8.65 6.85 8.72 13.64 6.71 9.09 9.51 14.77 12.15 8.9
P/B 3.80 4.94 6.27 4.75 4.50 7.90 4.86 8.34 8.03 13.08 10.19 6.6
EV/Sales 2.94 5.91 7.52 5.65 7.08 12.15 5.63 8.33 8.80 14.16 11.44 7.8
EV/FCF 13.38 53.67 32.34 22.59 45.01 49.53 42.14 121.76 40.71 76.28 41.48 49.7
Cash, $m
Cash, $m Operating cash flow 9 3 7 10 6 11 10 13 26 25 27 +11.4%
Capex (2) (1) 0 0 (1) (1) (2) (8) (9) (8) (2) +20.9%
Free cash flow 8 3 7 10 5 11 8 5 17 17 26 +8.6%
Balance, $m
Balance, $m Working capital 30 31 40 53 59 69 69 60 67 71 82 +10.0%
Net debt (26) (26) (34) (46) (52) (63) (58) (50) (52) (51) (63) +8.0%
Shareholders’ equity 32 33 42 56 61 72 74 71 87 95 106 +12.8%
Returns, %
Returns, % ROA 19.92 1.31 14.42 16.72 1.99 12.12 15.24 19.35 20.20 21.71 20.34 +1.8 pt
ROIC 109.91 12.19 49.58 58.28 (5.02) 63.44 62.16 57.82 39.69 37.60 41.79 (72.3) pt
ROE 22.61 1.54 16.84 19.76 2.34 13.96 17.59 23.70 24.31 24.78 23.42 +2.2 pt
People
People Employees 80 83 95 114 110 110 123 148 160 166 — +8.4%
Revenue/emp, $m 0.41 0.28 0.32 0.34 0.29 0.38 0.43 0.44 0.46 0.50 — +2.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

iRadimed Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47% Compare
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60% Compare
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63%
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
CBLL CeriBell, Inc. $1.0B — (loss-making) — (loss-making) +29.89% (above 0%: growing) n/m −19.65% (below 0%: shrinking) 89.77% (70.03%) Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
Median of peers $1.1B — — +11.94% — −10.61% 65.16% (7.23%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 780.60k 780.60k 368.00
2024 689.58k 689.58k 205.00
2023 642.57k 642.57k 175.00

Ownership

Directors and executive officers, together 34.60%
Roger Susi 34.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

iRadimed Corporation (IRMD) Latest News

4 Nov

Impact 3 · · Simply Wall St.

1 Nov

Impact 3 · · Simply Wall St.

30 Oct

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

23 Oct

Impact 3 · · GlobeNewswire

7 Aug

Impact 3 · · The Motley Fool transcript
Impact 3 ·

3 Aug

Impact 4 · transcript

1 Aug

Impact 3 · · Moby transcript

31 Jul

Impact 4 · · MarketBeat
Impact 3 ·

27 May

Impact 3 · · Insider Monkey

13 May

Impact 3 · · Simply Wall St.

2 May

Impact 4 · · GuruFocus.com
Impact 3 · · Moby

1 May

Impact 4 · · MarketBeat
Impact 4 · · Zacks
Impact 3 · · GlobeNewswire

30 Apr

Impact 3 · · Simply Wall St.

26 Apr

Impact 3 · · Insider Monkey

13 Apr

Impact 4 ·

13 Mar

Impact 4 · · Simply Wall St.

20 Feb

Impact 4 · · Insider Monkey

17 Feb

Impact 4 · · The Motley Fool

11 Feb

Impact 4 · · Simply Wall St.

10 Feb

Impact 4 · · GuruFocus.com
Impact 4 · · The Motley Fool
stockrow.com/IRMD · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com